IHI vs XLV: Which Is the Better Pick in 2026?

Overview

IHI and XLV are both equity ETFs focused on U.S. healthcare, but they slice the sector differently. IHI targets medical devices companies exclusively, while XLV provides broad sector exposure across pharmaceuticals, medical devices, biotechnology, and healthcare services as defined by the S&P 500's Health Care Select Sector Index. This difference in scope and construction drives meaningful divergence in yield, volatility, and fund scale.

How they differ

The biggest distinction is breadth: XLV mirrors the entire healthcare sector within the S&P 500, while IHI concentrates on the narrower medical devices subsector. This shows up immediately in AUM—XLV holds $43.4B against IHI's $3.56B—and in the funds' beta readings. XLV's 0.52 beta reflects the lower volatility of a diversified sector basket, while IHI's 0.79 beta indicates greater price swings typical of a focused industry play.

Yield tells a second story. XLV distributes 1.56% quarterly, compared to IHI's 0.63%. The higher XLV yield partly reflects the sector's recent dividend behavior and the inclusion of dividend-paying pharma and device makers across multiple sub-industries. IHI's lighter yield aligns with medical devices' historically lower payout ratios.

Fees run sharply in XLV's favor: 0.08% versus 0.37%. XLV's lower cost reflects its index-tracking structure and massive scale, while IHI's slightly higher ratio is typical for a more focused, actively-selected or narrower-benchmark fund.

Who each is best for

• IHI: Fits investors building a healthcare allocation who want to overweight the medical devices and diagnostics segment—companies selling equipment, implants, and monitoring tools—rather than holding broad pharma and biotech exposure.

• XLV: Designed for investors seeking comprehensive U.S. healthcare sector exposure without tilting toward any single sub-industry, and for those prioritizing lower costs and tighter tracking of the broader market's healthcare composition.

Key risks to know

• Sector concentration vs. subsector concentration: XLV carries healthcare sector risk (regulatory pressures on drug pricing, reimbursement changes); IHI amplifies that risk by excluding pharma diversification, leaving it more sensitive to medical device pricing, hospital capex cycles, and FDA approval timelines.

• Beta and volatility mismatch: IHI's 0.79 beta suggests meaningfully higher price volatility than XLV's 0.52 beta. In market downturns or during sector rotation, IHI may underperform more sharply.

• Yield sustainability gap: XLV's 1.56% yield is more than double IHI's, reflecting sector-wide dividend behavior but also requiring verification that the underlying holdings can sustain those payouts without capital return or NAV erosion. IHI, launched 05/01/2006, is smaller and newer, which may affect bid-ask spreads and index reconstitution tracking precision.

Bottom line

XLV suits investors wanting full-sector healthcare exposure at the lowest cost with higher current yield; IHI appeals to those with conviction that medical devices will outperform the rest of healthcare and willing to accept higher volatility and fees for that tilt. Before committing capital, verify that XLV's higher yield doesn't mask unsustainable distributions, and that IHI's narrower focus aligns with your sector outlook. Past performance doesn't guarantee future results.